Regeneron Pharmaceuticals Inc (REGN) Stock Analysis

Regeneron Pharmaceuticals Inc (REGN) is a publicly traded company in the HEALTHCARE sector. It trades at $602.92, carries a market capitalization of $62.97B, a price-to-earnings ratio of 14.66. This page summarizes the public market data, fundamentals, and frequently asked questions for REGN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Regeneron Pharmaceuticals Inc currently has a Neutral sentiment score of 0.14.

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. is a prominent American biotechnology firm headquartered in Westchester County, New York, renowned for its pioneering research and development in monoclonal antibodies and therapeutic proteins. With a diverse portfolio that spans critical therapeutic areas such as oncology, ophthalmology, and immunology, Regeneron is celebrated for its flagship products, including Eylea and Dupixent. The company boasts a strong and innovative pipeline, reflecting its unwavering...

GNG Research Analysis

GNG Research scores Regeneron Pharmaceuticals Inc (REGN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for REGN.

Frequently Asked Questions

Does REGN pay dividends?

Regeneron Pharmaceuticals Inc (REGN) does not currently pay a regular dividend.

What is REGN's P/E ratio?

Regeneron Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 14.66.

What is REGN's market cap?

Regeneron Pharmaceuticals Inc (REGN) has a market capitalization of $62.97B with a current stock price of $602.92.